Public funding was withdrawn before the start of the clinical trial.
PREPARE
Durability of Immunity Induced by the Ebolavirus Vaccine VSV-EBOV and As-sessment of a Booster Dose for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebolavirus Exposure
Sponsor study identifier
interventional
0
1 country
2
Study Start
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational risk for ebolavirus exposure
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 21, 2023
Actual (reported)July 25, 2023
Actual (reported)June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The course of Anti-EBOV immunoglobulin following primary vaccination
The course of Anti-EBOV immunoglobulin as measured by EBOV ELISA titers during the 24 months following primary vaccination
0-24month
Anti-EBOV immunoglobulin at 12 and 24 months follow-up
Anti-EBOV immunoglobulin as measured by EBOV ELISA titers at 12 and 24 months follow-up
12 month follow-up
Anti-EBOV immunoglobulin at 12 and 24 months follow-up
Anti-EBOV immunoglobulin as measured by EBOV ELISA titers at 12 and 24 months follow-up
24 month follow-up
Occurrence of Grade ≥ 3 AE until one month after primary and booster vaccination
1 month after primary vaccination
Occurrence of Grade ≥ 3 AE until one month after primary and booster vaccination
1 month after boost vaccination
Occurrence of SAE throughout the study
0-24 month
Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization And a single booster immunization with the same dose of study vaccine as the primary dose (≥72 million pfu/mL) at month 6 following primary vaccination
Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization only
intramuscular vaccination
intramuscular vaccination
University Hospital Frankfurt (KGU)
Frankfurt, 60590, Germany
Bernhard Nocht Centre for Clinical Trials (BNCCT)
Hamburg, 20359, Germany
Marylyn M Addo, Prof
Universitätsklinikum Hamburg-Eppendorf
0 participants (actual enrollment reported by the registry).
First Submitted
May 21, 2023
First Posted
July 25, 2023
Study Start
June 2026
Estimated (date passed)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 4, 2026
Record last verified: 2026-06
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: